Mark Purcell
Stock Analyst at Morgan Stanley
(1.06)
# 3,469
Out of 4,829 analysts
5
Total ratings
50%
Success rate
-9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $109.11 | +4.48% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $51.07 | +7.70% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $37.26 | +18.09% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $68.76 | +23.62% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $67.39 | +78.07% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $109.11
Upside: +4.48%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $51.07
Upside: +7.70%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $37.26
Upside: +18.09%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $68.76
Upside: +23.62%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $67.39
Upside: +78.07%